Persistent acne in women: Implications for the patient and for therapy

American Journal of Clinical Dermatology

Volumn 7, Issue 5, 2006, Pages 281-290

  Williams, Christina ^a   Layton, Alison M ^a  

^a HARROGATE AND DISTRICT NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CHLORMADINONE; CLINDAMYCIN; CORTICOSTEROID; COSMETIC; CYPROTERONE; DESOGESTREL; DIANE; DOXYCYCLINE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ERYTHROMYCIN; ESTROGEN; ETHINYLESTRADIOL; FLUTAMIDE; GESTAGEN; GONADORELIN; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE; NICOTINAMIDE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; RETINOID; SPIRONOLACTONE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ACNE; AUTOIMMUNE HEPATITIS; BREAST TENDERNESS; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; FACE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; INFLAMMATION; INTRACRANIAL HYPERTENSION; JAW; LIVER TOXICITY; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MENSTRUAL IRREGULARITY; NAUSEA; NECK; NEPHROTOXICITY; ONYCHOLYSIS; OVARY POLYCYSTIC DISEASE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROPIONIBACTERIACEAE; REVIEW; SEBUM SECRETION; SIDE EFFECT; SKIN PIGMENTATION; SMOKING; STRESS; UNSPECIFIED SIDE EFFECT; ACNE VULGARIS; TOPICAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANDROGEN ANTAGONISTS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; RETINOIDS;

EID: 34347221247     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200607050-00002     Document Type: Review

References (65)

1. Burton JL, Cunliffe WJ, Stafford L, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971; 85: 119-26
2. Goulden V, Stables GI, Cunliffe WJ. The prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41: 577-80
3. Shafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001; 145: 100-4
4. Goulden V, Clark SM, Cunliffe WJ. Post adolescent acne: a review of clinical features. Br J Dermatol 1997; 136: 66-70
5. Marks R. Acne and its management beyond the age of 35 years. Am J Clin Dermatol 2004; 5 (6): 459-62
6. Gollnick MD, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49: S1-38
7. McGeown CH, Goulden V, Holland D, et al. Sebum excretion in post adolescent acne compared to controls and adolescent acne [abstract]. J Invest Dermatol 1997; 108: 386
8. Sheehan-Dare RA, Hughes BR, Cunliffe WJ. Clinical markers of androgenicity in acne vulgaris. Br J Dermatol 1988 Dec; 119 (6): 723-30
9. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004 Sep-Oct; 22 (5): 419-28
10. Vershoore M. Aspect hormonaux de l'acne. Ann Dermatol Venereol 1987; 114: 439-54
11. Lawrence D, Shaw M, Katz M. Elevated free testosterone concentration in men and women with acne vulgaris. Clin Exp Dermatol 1986; 11: 263-73
12. Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983; 81: 70-4
13. Pochi PE, Comite H, Longcope C. Hormone blood levels in women with acne [abstract]. J Invest Dermatol 1986; 86: 501
14. Sultan C, Oliel V, Audran F, et al. Free and total plasma testosterone in men and women with acne. Acta Derm Venereol (Stockh) 1986; 66: 301-4
15. Lookingbill DP, Horton R, Demers LM, et al. Tissue production of androgens in women with acne. J Am Acad Dermatol 1985; 12: 481-7
16. Carmina E, Lobo RA. Evidence for increased androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab 1993; 76: 1111-4
17. Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999; 135: 1041-5
18. Allam SG. Acne vulgaris in the sixth decade and beyond [Master of Science thesis]. Cardiff: University of Wales, 1991
19. Eady EA, Gloor M, Lleyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206: 54-6
20. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51-7
21. Ozolins M, Eady EA, Avery A, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004; 364: 2188-95
22. Till AE, Goulden V, Cunliffe WJ, et al. The cutaneous microflora of adolescent, persistent and late-onset acne patients does not differ. Br J Dermatol 2000; 142: 885-92
23. Mills OH, Kligman AM. Acne detergicans. Arch Dermatol 1975 Jan; 111 (1): 65-8
24. Kligman AM, Mills Jr OH. 'Acne cosmetica'. Arch Dermatol 1972; 106 (6): 843-50
25. Khanna N, Gupta SD. Acneiform eruptions after facial beauty treatment. Int J Dermatol 1999; 38 (3): 196-9
26. Cunliffe WJ. Clinical features of acne. In: Marks R, editor. Acne. London: Martin Dunitz, 1989: 11-75
27. Kligman AM. Post adolescent acne in women. Cutis 1991; 48: 75-7
28. Knaggs HE, Wood EJ, Rizer RL, et al. Post adolescent acne. Int J Cosmet Sci 2004; 26: 129-38
29. Cunliffe WJ. Acne and unemployment [letter]. Br J Dermatol 1986; 115: 386
30. Layton AM, Seukaran D, Cunliffe WJ. Scarred for life? Dermatology 1997; 195: 15-21
31. Myhill JE, Leichtmen SR, Burnett JW. Self-esteem and social assertiveness in patients receiving isotretinoin treatment for cystic acne. Cutis 1988; 41: 171-3
32. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998; 134: 454-8
33. Derman RJ. Androgen excess in women. Int J Fertil Menopausal Stud 1996 Mar-Apr; 41 (2): 172-6
34. McLaughlin B, Barrett P, Finch T, et al. Late-onset adrenal hyperplasia in a group of Irish females who presented with hirsutism, irregular menses and/or cystic acne. Clin Endocrinol 1990; 32: 57-64
35. Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis 2004 Jun; 73 (6 Suppl.): 6-10
36. Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne. J Dermatolog Treat 1995; 6 Suppl. 1: S8-10
37. Dreno B, Bettoli V, Ochsendorf F. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004; 14 (6): 391-9
38. Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother 2005 Mar; 6 (3): 409-18
39. Shaw JC, White LE. Persistent acne in adult women. Arch Dermatol 2001; 137: 1252-3
40. DeRossi SS, Hersh EV. Antibiotics and oral contraceptives. Dent Clin North Am 2002; 46 (4): 653-4
41. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and thera-pies. Semin Cutan Med Surg 2001; 20: 144-53
42. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25-34
43. Shaw JC. Hormonal therapy in dermatology. Dermatol Clin 2001; 19: 169-78
44. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984; 111: 209-14
45. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43: 498-502
46. Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 2005 Mar; 19 (2): 163-6
47. Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23: 462-9
48. Manso G, Thole Z, Salquiero E, et al. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish Pharmacovigilance Sys-tem. Pharmacoepidemiol Drug Saf 2006 Apr; 15 (4): 253-9
49. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol 2002; 3 (8): 571-8
50. Ostlere LS, Rumsby G, Holownia P, et al. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne. Clin Endocrinol 1998; 48: 209-15
51. Saihan E, Burton J. Sebaceous gland suppression in female acne patients by combined glucocorticoid-oestrogen treatment. Br J Dermatol 1981; 103: 139-42
52. Pochi P, Strauss J. Sebaceous gland inhibition from combined glucocorticoid-estrogen treatment. Arch Dermatol 1976; 112: 1108-9
53. Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194 (4): 351-7
54. Committee for Proprietary Medicinal Products (CPMP). Summary information on a referral opinion following an arbitration pursuant to article 30 of directive 2001/83/ED, for Roaccutane and associated names [online]. London: European Agency for the Evaluation of Medicinal Products, 2003. Available from URL: http://www.emea.eu.int/pdfs/human/referral/isotretinoin/281103en.pdf [Ac-cessed 2006 Sep 13]
55. Committee for Proprietary Medicinal Products (CPMP). Annex III: amended summary of product characteristics of the reference member state [online]. London: European Agency for the Evaluation of Medicinal Products, 2003. Available from URL: http://www.emea.europa.eu/pdfs/human/referral/roaccutane/ 284603en1.pdf [Accessed 2006 Sep 13]
56. Committee for Proprietary Medicinal Products (CPMP). Annex II: scientific Conclusions and grounds for amendment of the summary(ies) of product characteristics presented by the EMEA [online]. London: European Agency for the Evaluation of Medicinal Products, 2003. Available from URL: http://www.emea. europa.eu/pdfs/human/referral/roaccutane/284603en1.pdf [Accessed 2006 Sep 13]
57. US FDA Center for Drug Evaluation and Research. Alert for healthcare professionals: isotretinoin (marketed as Accutane) [online]. Rockville (MD): FDA, 2005. Available from URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/ IsotretinoinHCP. htm [Accessed 2006 Sep 13]
58. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005 Jun; 24 (2): 92-102
59. Goulden V, Clark SM, McGeown C, et al. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997 Jul; 137 (1): 106-8
60. Zane LT. Acne maintenance therapy: expanding the role of topical retinoids? Arch Dermatol 2006 May; 142 (5): 638-40
61. Goulden V, Clark SM, Cunliffe WJ. Treatment of adult acne with low-dose intermittent isotretinoin [abstract]. Br J Dermatol 1996; 135: 20
62. Cunliffe WJ. Treatment of acne. In: Cunliffe WJ, editor. Acne. London: Martin Dunitz Ltd, 1991: 252-87
63. Breathnach AS. Melanin hyperpigmentation of skin. Cutis 1996; 57: 36-45
64. Pepall LM, Cosgrove MP, Cunliffe WJ. Ablation of whiteheads by cautery under topical anaesthetic. Br J Dermatol 1991; 125: 256-9
65. Atzori L, Brundu MA, Orru A. Glycolic acid peeling in the treatment of acne. J Eur Acad Dermatol Venereol 1999; 12: 119-22